This article is for patients on the DOTATATE track - people with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have completed one course of PRRT (peptide receptor radionuclide therapy) with lutetium Lu 177 dotatate and whose tumors are growing again. If that's your situation, one of the first questions your care team or you may ask is whether a second course is possible. The short answer is sometimes yes. But eligibility has specific requirements, and the decision gets harder the second time around.
PRRT with lutetium Lu 177 dotatate - sold under the brand name Lutathera in many markets - was approved by the U.S. Food and Drug Administration in January 2018 for adults with somatostatin receptor-positive GEP-NETs. The approval was based on the landmark NETTER-1 phase 3 trial published in The New England Journal of Medicine. The standard first course is four cycles at 7.4 GBq (200 mCi) each, spaced roughly eight weeks apart. This article focuses on what happens if your tumor grows again after those four cycles.
What Does Retreatment Mean in the Context of PRRT?
Retreatment means you get more cycles of Lu-177 DOTATATE after your first four-cycle course ends and your disease starts growing again. Progression typically means your tumor has increased in size on imaging - confirmed by a CT scan, MRI, or a follow-up Ga-68 DOTATATE PET-CT scan.
Retreatment is different from maintenance therapy (occasional low doses to extend a response). It's also different from a one-time salvage cycle. Different centers use different terms, but the key question is the same: can your tumor be treated again with Lu-177 DOTATATE, and is it safe for your body?
Retreatment with PRRT isn't yet a standard approach like the first four cycles are. Experienced centers offer it on a case-by-case basis and always require a formal eligibility review before you start.
What Does the Evidence Show About a Second Course?
The evidence for PRRT retreatment is growing, though most comes from studies of past cases and real-world data rather than large randomized controlled trials. That matters when you read the numbers.
One study of repeat PRRT with Lu-177 DOTATATE found that among eligible patients, roughly 50% had partial response (tumor shrinkage), about 42% had stable disease, and around 8% had continued progression, according to peer-reviewed research. A U.S. center tracked 31 patients and found a median progression-free survival of 20.2 months after the initial PRRT course and 9.6 months after retreatment - suggesting that a second course may still help control disease even if the effect is shorter than the first, as noted in the Neuroendocrine Tumor Research Foundation's 2024 report.
Another analysis found a median progression-free survival of about 17.5 months after a second PRRT course in a selected patient group, based on a single-center study. An ongoing clinical trial - the NET RETREAT Trial - is comparing Lu-177 DOTATATE retreatment with standard targeted therapies such as everolimus, sunitinib, or cabozantinib in patients whose disease progressed after initial PRRT. Results are expected on ClinicalTrials.gov. An Australian PRRT service reviewed eleven years of data and found that retreatment was offered to a significant subset of patients who had progressed after their first course, supporting the view that retreatment is practical in the right clinical setting, as discussed in a U.S. real-world outcomes study.
Who May Be Eligible for a Second PRRT Course?
A nuclear medicine team will assess five factors when reviewing retreatment eligibility. This is not a self-check - each factor requires clinical evaluation - but understanding them helps you have a more informed conversation.
- Somatostatin receptor expression still present on imaging. A repeat Ga-68 DOTATATE PET-CT scan is usually needed. It shows whether your tumor lesions still take up the radiotracer at a level high enough for treatment to work. If receptor expression has dropped significantly since your first course, retreatment won't work. Our guide to how Ga-68 DOTATATE PET determines PRRT eligibility explains what to look for in your scan report.
- Kidney function that can support more cycles. Each PRRT cycle delivers radiation to the kidneys. A measured GFR (glomerular filtration rate - a score for how well your kidneys filter blood) of at least 50 mL/min/1.73 m2 is typically required. For retreatment, your kidney function is tested again to confirm whether additional exposure is safe. If it has dropped significantly after the first course, further cycles may not work.
- Adequate bone marrow function. Blood counts - white cells, red cells, and platelets - must be sufficient before each additional cycle. Prior PRRT can reduce bone marrow reserve over time, so counts are checked before treatment and throughout retreatment.
- Performance status of 2 or better. Most criteria require a WHO performance status of 2 or better. This means you can handle some self-care and aren't bedridden for more than half your waking hours.
- Confirmed disease progression on imaging. Retreatment is generally considered when imaging clearly shows tumor growth after your initial course - not as a preventive measure when disease is stable. If your tumor stayed stable after four cycles, the usual approach is to keep watching rather than start retreatment.
What Assessments Take Place Before Retreatment?
Before a second course is approved, your team will typically gather:
- A recent Ga-68 DOTATATE PET-CT scan (usually within the past three to four months) to confirm somatostatin receptor uptake
- A CT scan or MRI to confirm progression using standard criteria
- Blood tests checking kidney function (GFR), liver enzymes, and blood counts
- A review of your total PRRT dose from your first course
- At some centers, a dosimetry assessment - a calculation of the actual radiation dose your kidneys and bone marrow already absorbed - to estimate what additional dose these organs can safely receive
Most centers don't yet require dosimetry, but experienced PRRT programs increasingly use it to personalize retreatment decisions. It's particularly helpful for patients whose kidneys or bone marrow showed stress during their initial course. If you want a thorough review of your eligibility before committing to travel or treatment, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you (and what alternatives exist if not), including a structured review of your current imaging and organ function results.
What Does a Second Course Look Like in Practice?
If your care team approves retreatment, the logistics are similar to your first course. Cycles are typically spaced eight weeks apart. The number of additional cycles - whether two, three, or four - depends on your total dose history, organ tolerance, and how your tumor responds during early retreatment cycles. You may not be able to complete as many cycles as the first time.
In some cases, your nuclear medicine team may lower the dose per cycle to protect kidneys or bone marrow. This is based on dosimetry calculations. Between cycles, you'll get blood tests and possibly repeat imaging to check response and watch for side effects. Your team may pause or stop retreatment early if you develop significant toxicity or if the tumor doesn't respond.
What Are the Main Risks With Retreatment?
The risks of retreatment are broadly similar to those of the first course, but cumulative radiation exposure is an important extra consideration.
Kidney toxicity is the most significant long-term concern. Each cycle adds to the total dose your kidneys absorb over your lifetime of PRRT. A small percentage of retreated patients develop serious kidney toxicity. Amino acid infusions - given alongside each PRRT cycle to protect the kidneys - remain essential during retreatment, just as in the first course.
Bone marrow suppression is the other main risk. Low blood counts - including anemia, low platelets, and reduced white cells - can occur and may be worse with more cycles. Myelodysplastic syndrome (a rare but serious condition where bone marrow produces abnormal blood cells) develops in a small percentage of retreated patients. This requires ongoing monitoring with routine blood counts after each cycle and in follow-up.
Short-term side effects such as nausea, fatigue, and mild stomach discomfort during and after infusion days are similar to what many patients experience during a first course. If you had carcinoid syndrome symptoms during your initial treatment, similar flares may occur during retreatment. Our article on whether PRRT can control carcinoid syndrome symptoms covers what to expect and when to contact your team.
Between cycles, focus on taking care of yourself. Some patients use over-the-counter products alongside their medical team's guidance. If you're interested in options to support your immune system, you can explore what's available - but always discuss any supplement with your oncologist first, as some can interfere with treatment or change lab results.
What If Retreatment Is Not an Option for You?
Not every patient who progresses after initial PRRT will qualify for a second course. Retreatment may not work if:
- Somatostatin receptor expression is lost or too low for effective therapy
- Your kidney function dropped significantly since the first course
- Your bone marrow doesn't have enough reserve for further cycles
- Your tumor changed to a higher grade (for example, a low-grade NET that transformed or de-differentiated)
- Your overall performance status dropped substantially
If retreatment won't work for your case, you still have active options. These include continued or adjusted somatostatin analogue therapy, targeted therapies such as everolimus or sunitinib for pancreatic NETs, chemotherapy for higher-grade tumors, or enrollment in a clinical trial. Our article on what to do when Lu-177 DOTATATE stops working explores these pathways in detail and what questions to raise with your team.
Accessing PRRT Retreatment in India
International patients from the GCC countries, East Africa, South Asia, Southeast Asia, and other regions where PRRT is unavailable or very expensive can access retreatment at established nuclear medicine centers in India. The process for retreatment access is similar to that for a first course. You will typically need to share your most recent Ga-68 DOTATATE PET-CT scan, a CT or MRI documenting progression, current blood test results, and a written summary of your prior PRRT treatment - including cycle dates and total administered activity.
Your treating center will determine the number of additional cycles after reviewing your case. Our practical guide to travel costs for international NET patients coming to India for PRRT covers what to budget and what to plan for before you arrive.
To begin the retreatment eligibility process, you can submit your records through the Lutetium Therapy contact form. If retreatment isn't right for your case now, the team will suggest other options based on your situation.
When to Talk to Your Doctor
If your most recent imaging shows tumor growth after completing your initial PRRT course, speak with your oncologist or nuclear medicine specialist about retreatment. Ask specifically whether you need a repeat Ga-68 DOTATATE PET-CT scan to check your current receptor expression, and whether your current kidney function and blood counts can handle additional cycles. If your current center doesn't have a retreatment program, ask for a referral to one that does - or seek a second opinion through a specialist PRRT program.
This article is general information only, not medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How many times can you have PRRT with Lu-177 DOTATATE?
The standard initial course is four cycles. Beyond that, additional cycles may be possible if you remain eligible - meaning somatostatin receptor expression is still confirmed on a Ga-68 DOTATATE PET-CT scan, kidney function remains adequate, and bone marrow reserve is sufficient. There is no universally fixed upper limit. Decisions are made individually based on cumulative dose received, organ function tests, tumor response, and overall health. Some patients have received two or more separate treatment courses at experienced centers.
How long do you wait between PRRT courses before retreatment?
There is no fixed waiting period, but retreatment is generally only considered after confirmed radiological progression - meaning your imaging clearly shows tumor growth after your first course ended. This may be months to over a year after your last cycle. The interval also depends on how fully your kidneys and bone marrow have recovered from the initial course. Your nuclear medicine team will assess this before approving any additional cycles.
Does a second PRRT course work as well as the first?
Research suggests that retreatment can produce meaningful disease control, though outcomes may differ from the first course. One peer-reviewed study found approximately 50% of retreated patients showed a partial response and about 42% had stable disease. Real-world data from a U.S. center found a median progression-free survival of 9.6 months after retreatment compared with 20.2 months after the initial course. Individual results vary based on tumor biology, receptor expression level, and how the disease responded to the first course.
Is PRRT retreatment available in India for international patients?
Yes. Several Indian cancer centers that offer PRRT also provide retreatment for eligible patients who have progressed after a first course. The eligibility assessment process is similar to that for an initial course. International patients typically need to share recent imaging (including a Ga-68 DOTATATE PET-CT), current blood test results, and a summary of prior PRRT treatment before a center can confirm whether retreatment is suitable.
What are the biggest risks of receiving a second PRRT course?
The main concerns are cumulative kidney toxicity and bone marrow suppression. Each cycle adds to the total radiation dose your kidneys have received over your treatment history, so kidney function is monitored closely throughout. Blood counts can also decline cumulatively with repeated cycles. Myelodysplastic syndrome - a rare but serious bone marrow condition - has been observed in a small percentage of patients in retreatment studies. Amino acid infusions to protect the kidneys remain essential, as they are in the first course. Your team will assess cumulative organ dose before approving any additional cycles.
What scan confirms eligibility for PRRT retreatment?
A Ga-68 DOTATATE PET-CT scan - also called somatostatin receptor imaging - is typically required before retreatment. This confirms whether your tumor cells still express somatostatin receptors and take up the radiotracer at a level high enough for treatment to be effective. If receptor expression has dropped significantly since your first course, retreatment is generally not recommended, because the therapy relies on the tumor binding the radiotracer to receive its dose. A CT scan or MRI documenting disease progression is also usually required alongside the PET-CT.
